LEAN Optimization in Multiple Sclerosis

Global biopharmaceutical company

LEAN Optimization in Multiple Sclerosis

Discover how LEAN methodology revolutionizes Multiple Sclerosis treatment, enhancing patients’ lives and medical efficiency.

The Challenge

MS affects around 1.8 million people in the whole world. Although there is no cure, pharmaceutical advances offer drugs that reduce the frequency of relapses and slow the progression of the disease. In this context, our client faced the challenge of maximizing access to more innovative and effective medicines for a specific group of MS patients. To achieve this, they needed to remove the added complexity of involving different Healthcare Professionals (HCPs) in the prescription and administration process. Both hospitals and professionals tended to deprioritize these more effective drugs over traditional ones.

“Recognizing the suitability of the LEAN methodology, the pharmaceutical company provided hospitals with an efficient protocol that included the new drug.”

The approach

Eraneos applied the LEAN methodology to systematize the process, enhancing treatment effectiveness for a larger group of patients and improve their journey. Recognizing the suitability of the LEAN methodology, the pharmaceutical company provided hospitals with an efficient protocol that included the new drug. Proper drug administration and coordination within a multidisciplinary team were critical.

We conducted several workshops with the professionals involved in the process to map the patient journey and address key pain points, thereby reducing barriers and defining new, innovative, and low-effort solutions with a high impact on the quality of life for patients.

Our client is a leading research-focused biopharmaceutical company. They are focused on drug discovery and development in therapeutic areas such as immunology, neurology and ophthalmology. The client is active in more than 75 countries

The results

The implementation of LEAN has yielded significant results:

  • Increased market access: Process improvements facilitated more efficient drug entry to the market, benefiting a greater number of MS patients. This breakthrough overcame internal barriers in hospitals, promoting the prioritization of the drug over similar alternatives.
  • Expanded treatment: Process optimization led to a higher number of patients receiving treatment with the new drug, enhancing medical care for MS patients.
  • Improved quality of life: Systematizing procedures ensured the correct administration of the drug, which helped to improve patients’ quality of life by reducing the frequency of relapses and side effects. The multidisciplinary team provided enhanced emotional support.

In summary, the application of LEAN in the Multiple Sclerosis Unit not only optimized internal processes, but also produced significant outcomes, increased market penetration, expanded patient treatment, and substantially improved the quality of life for those affected by MS. This experience underscores the effectiveness of the LEAN methodology in hospital settings, focusing on tangible results that benefit patients and the healthcare system.

Let’s create sustainable change together.